Citius Pharmaceuticals CTXR
NASDAQ CTXR
$0.48 -0.01 (-2.48%)
As of: Nov 11, 2026 · 3:57 PM EST

Citius Pharmaceuticals (CTXR) EBITDA Margin (2016)

Updated

Citius Pharmaceuticals (CTXR) reported EBITDA Margin of -56764966.67% for fiscal Q4 2016 (quarter ended Sep 30, 2016).

Analysis

Citius Pharmaceuticals (CTXR) EBITDA Margin (2016) Analysis & Trends

For FY2016 (ended Sep 30, 2016), Citius Pharmaceuticals posted EBITDA Margin of -924063.03%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 Citius Pharmaceuticals 13.45 Mn -10.82 Mn 1.00 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2016 -56,764,966.67%
API Access

Citius Pharmaceuticals EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CTXR&period=max&api_key=YOUR_API_KEY